Yubin Kang

Phase I/II Clinical Trial of In-House BCMA CAR T-Cell Therapy and Opaganib in Ultrahigh Risk Multiple Myeloma

National Cancer Institute · R01

Contact PI · $628.6K · University of Oklahoma Hlth Sciences Ctr

Thioredoxin Derivatives for Radiation Mitigation

National Institute of Allergy and Infectious Diseases · U01

Contact PI · $1M · University of Oklahoma Hlth Sciences Ctr

Role of SLAMF7 in Racial Disparities in Myeloma

National Cancer Institute · R21

Contact PI · $413.6K · Duke University

Enhancing CAR T Therapy in Multiple Myeloma

National Cancer Institute · R21

Contact PI · $410.2K · Duke University

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Principal investigator · Recruiting · Phase 2

Duke University

Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Principal investigator · Completed

Duke University

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Principal investigator · Terminated · Phase 1, Phase 2

RedHill Biopharma Limited